Table 3. IAT and ATWB events.
Data represented as n (%); p value calculated by chi-square; *Combination of any two or more CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors; †Any other antineoplastic treatment not belonging to the class of ICIs specifically listed.
ATWB, elevated AT levels along with elevated bilirubin; CTLA-4, cytotoxic T-lymphocyte–associated protein 4; Gr, grade; IAT, isolated elevation of AT levels; ICI, immune checkpoint inhibitor; ICI Comb, combinations of ICIs; N, total number of events; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.
| Treatment class | Treatment courses (%) | IAT | ATWB | ||||
| Gr 3 | Gr 4 | Total | Gr 3 | Gr 4 | Total | ||
| N (%) | 85,433 (100) | 1,630 (1.91) | 169 (0.20) | 1,799 (2.11) | 378 (0.44) | 63 (0.07) | 441 (0.52) |
| CTLA-4 inhibitors | 2,526 (2.96) | 69 (2.73) | 7 (0.28) | 76 (3.01) | 14 (0.55) | 2 (0.08) | 16 (0.63) |
| PD-1 inhibitors | 57,421 (67.21) | 949 (1.65) | 84 (0.15) | 1,033 (1.80) | 247 (0.43) | 30 (0.05) | 277 (0.48) |
| PD-L1 inhibitors | 7,608 (8.91) | 71 (0.93) | 4 (0.05) | 75 (0.99) | 14 (0.18) | 1 (0.01) | 15 (0.20) |
| ICI Comb* | 5,274 (6.17) | 305 (5.78) | 54 (1.02) | 359 (6.81) | 48 (0.91) | 25 (0.47) | 73 (1.38) |
| ICI plus antineoplastic† | 12,604 (14.75) | 236 (1.87) | 20 (0.16) | 256 (2.03) | 55 (0.44) | 5 (0.04) | 60 (0.48) |
| p value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |